Interview, Fireside Chat
A Conversation with FDA Commissioner Robert Califf | Future of Health Summit 2024
- Commissioner Califf reflects on his two stints at the FDA, noting he was appointed on the day of the Abbott infant formula recall and was immediately thrust into that crisis.
- He identifies the reorganization of the FDA Food Program as a primary legacy achievement, noting the management of a $8,000 budget and oversight of over one million establishments within a complex global supply chain.
- Califf emphasizes that the majority of the FDA's food budget is allocated to inspections rather than nutrition programs.
- He highlights cross-departmental collaboration, specifically regarding recent changes to rare disease regulations, as a key success in leveraging explosive scientific advancements.
- While acknowledging the U.S. as a global "gold standard" for innovation and regulatory science, Califf states that 90% of drug and device development efforts still fail to work.
- Califf argues that the U.S. faces a delivery crisis rather than an innovation deficit, citing that the nation ranks last among high-income countries in healthcare access and life expectancy.
- He rejects the notion that AI can replace human care, asserting that digital tools must serve as support for human interactions rather than substitutes.
- The Commissioner warns that AI models integrated into clinical environments pose risks of unmonitored drift, noting the FDA lacks current ecosystem-level monitoring systems for generative AI.
- Califf suggests the FDA is well-situated to regulate AI used in drug discovery (e.g., protein folding) but identifies decision support within healthcare delivery as the area requiring new regulatory frameworks.
- Regarding evidence generation, he advocates for diversity action plans that cover the entire drug development program rather than focusing solely on Phase 3 trial requirements.
- He contends that clinical trials cannot structurally correct systemic biases, particularly the widening gap between rural and urban populations and the net wealth divide.
- Califf proposes shifting focus to post-market pragmatic trials to address representation of the world's 250+ ethnicities and to evaluate real-world treatment value.
- He criticizes the current approval paradigm for not answering questions regarding comparative effectiveness, treatment combinations, or optimal dosing post-approval.
- The Commissioner outlines three critical qualities for the next FDA leader: executive capability to listen to experienced stakeholders, a commitment to generating high-quality evidence, and respect for civil servants making decisions with minimal political influence.
- He clarifies that while product-specific decisions must remain science-based, policy decisions affecting groups of products inherently involve political considerations.